Pharmacologic Management of Co‑Occurring Alcohol and Cannabis Use Disorder

Acamprosate – First‑Line Therapy for Alcohol Dependence

In adults with concurrent alcohol and cannabis use, acamprosate is the preferred first‑line medication to reduce alcohol cravings and maintain abstinence because it does not undergo hepatic metabolism and carries no hepatotoxicity risk【1】【2】【3】.
Acamprosate attenuates withdrawal symptoms and cravings by modulating the glutamatergic receptor system【2】【4】 (moderate‑quality mechanistic evidence).
Recommended dose is 1,998 mg per day for patients weighing ≥ 60 kg (reduced by one‑third for < 60 kg), initiated 3–7 days after the last drink and continued for at least 3–6 months【3】【6】.
A meta‑analysis of 24 randomized controlled trials demonstrated that acamprosate significantly reduces the likelihood of returning to heavy drinking compared with placebo【2】【4】 (high‑level evidence).

Gabapentin (600–1,800 mg/day) can be used as a second‑line agent to lower heavy‑drinking days and improve withdrawal symptoms, but renal function and sedation must be closely monitored, especially in patients who also use cannabis【5】 (moderate‑quality evidence).
Baclofen (30–60 mg/day, typically 10 mg three times daily) is the only medication specifically studied in patients with cirrhosis and may be considered when liver disease is present【2】【4】【7】 (limited‑quality evidence). It should be avoided in patients with hepatic encephalopathy because of potential mentation impairment【5】.

Naltrexone should be avoided despite its efficacy for reducing heavy‑drinking days because of documented risk of hepatocellular injury and hepatotoxicity, and because it has not been tested in patients with alcoholic liver disease【1】【2】【3】【4】【6】 (moderate‑quality safety evidence).
Disulfiram is not recommended due to possible hepatotoxicity in severe alcoholic liver disease, poor tolerability, and limited evidence of benefit for sustained abstinence【2】【4】【1】 (low‑to‑moderate‑quality evidence).

Although no FDA‑approved pharmacotherapies exist for cannabis use disorder, combining pharmacologic treatment for alcohol dependence with cognitive‑behavioral therapy (CBT) or other evidence‑based counseling improves outcomes over usual care alone【9】 (moderate‑quality evidence).

Acamprosate should be started only after acute withdrawal symptoms have resolved【3】【6】; therapeutic plasma concentrations are typically achieved within 1–2 weeks【3】, and treatment should be maintained for a minimum of 3–6 months【3】【6】.
When gabapentin is used, clinicians must monitor renal function and watch for worsening mental status or excessive sedation, with particular vigilance in patients using both alcohol and cannabis【5】.
Overall, pharmacotherapy must be paired with structured counseling (e.g., CBT, motivational enhancement, contingency management) to achieve optimal results; medications alone are insufficient【1】【3】【9】.

Strict abstinence from alcohol is essential, as continued drinking accelerates liver disease progression【1】.
Recidivism rates after treatment are high (67–81 % within one year), underscoring the need for ongoing support and monitoring【1】.